Physician profile
Ramin Saghafi
NPI 1376770800
$11,042.77
in general payments reported to CMS, 2019-2025
39 companies · $6,581 in 2025
The $6,581 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $577 · 2021: $270 · 2022: $846 · 2023: $758 · 2024: $790 · 2025: $6,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,560 · Food and Beverage: $2,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,559.80 |
| Food and Beverage | $2,568.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,529.53 | 2025 | |
| Glaxosmithkline, LLC. | $1,570.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.85 | 2019-2025 | Ofev |
| Genzyme Corporation | $463.25 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $430.16 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Grifols USA, LLC | $364.52 | 2019-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $207.52 | 2019-2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $192.40 | 2023-2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $135.30 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $128.26 | 2019-2025 | Uptravi, Opsumit |
| Pulmonx Corporation | $110.92 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $90.85 | 2021-2024 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $68.39 | 2019-2022 | |
| Insmed, INC. | $68.24 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $66.98 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Saghafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.